Fermenta Biotech Ltd

Fermenta Biotech Ltd exhibits a capital structure with a debt-to-equity ratio of 0.48, indicating a relatively balanced mix of debt and equity financing. The company's liquidity position is characterized by a current ratio of 1.4, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents amount to INR 1.7 million, which is significantly lower than its long-term debt of INR 1.39 billion, raising concerns about its ability to meet long-term obligations without additional financing.

Profitability metrics for Fermenta Biotech Ltd are weak, with a return on equity (ROE) of -2.4% and a return on assets (ROA) of -1.27%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a red flag for investors. The company's operating income is negative at INR -10.83 million, and its net income is also negative at INR -69.41 million, reflecting poor operational performance and a lack of profitability.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another.

Fermenta Biotech Ltd's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is positive at INR 1.05 billion, which is a positive sign, but this is offset by a significant capital expenditure of INR -192.07 million. The company's ability to sustain growth will depend on its capacity to convert this cash flow into profitable investments and to manage its capital expenditures effectively.

The company faces several risk factors, including liquidity concerns due to its negative net cash position after accounting for total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk, suggesting that while the company may need to raise additional capital, the likelihood of significant share dilution is currently low. The company's financial leverage and negative net income also contribute to its overall risk profile.

Recent financial filings and transcripts do not provide specific details on new product launches, partnerships, or strategic initiatives. The company's financial performance and risk profile suggest that it is in a challenging phase, and investors should closely monitor its ability to improve profitability and manage its debt obligations.

Revenue surged 39.9% year-over-year to INR 4.69 billion, demonstrating strong top-line growth momentum in the latest fiscal period.

Net income rebounded sharply with a 433.3% year-over-year increase to INR 768.6 million, signaling a robust return to profitability.

Free cash flow turned positive at INR 747.1 million, marking a 435.2% improvement and indicating restored operational cash generation.

Long-term debt decreased significantly to INR 1.15 billion, reducing leverage and strengthening the company's overall balance sheet position.

Operating income expanded by 2200.8% year-over-year to INR 905.4 million, highlighting a dramatic recovery in core operational efficiency.

Operating margin remains negative at -1.1%, falling well below the pharmaceutical cohort median of 5.45% and indicating weak profitability.

Cash conversion ratio sits at -15.18%, placing it in the bottom quartile compared to the cohort median of 0.95.

The company faces medium liquidity risk, which could constrain its ability to meet short-term financial obligations effectively.

Revenue INR 3.36B, −4,1% YoY; Operating income +88,7% YoY.

• ▍Revenue INR 3.36B, −4,1% YoY
• ▍Operating income +88,7% YoY
• ▍Net income +55,2% YoY
• ▍Free cash flow +69,0% YoY
• ▍Net margin -6.9%

Revenue INR 3.50B, −12,2% YoY; Operating income −206,0% YoY.

• ▍Revenue INR 3.50B, −12,2% YoY
• ▍Operating income −206,0% YoY
• ▍Net income −433,4% YoY
• ▍Free cash flow −998,6% YoY
• ▍Net margin -14.7%

Revenue INR 3.99B, +5,6% YoY; Operating income −42,6% YoY.

• ▍Revenue INR 3.99B, +5,6% YoY
• ▍Operating income −42,6% YoY
• ▍Net income −66,1% YoY
• ▍Free cash flow −230,8% YoY
• ▍Net margin 3.9%

Revenue INR 3.77B; Operating income INR 626.2M.

• ▍Revenue INR 3.77B
• ▍Operating income INR 626.2M
• ▍Net margin 12.1%